JP2017525755A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525755A5
JP2017525755A5 JP2017519448A JP2017519448A JP2017525755A5 JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5 JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
linker
compound according
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017519448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036414 external-priority patent/WO2015195904A1/en
Publication of JP2017525755A publication Critical patent/JP2017525755A/ja
Publication of JP2017525755A5 publication Critical patent/JP2017525755A5/ja
Pending legal-status Critical Current

Links

JP2017519448A 2014-06-20 2015-06-18 Her2抗体−薬物抱合体 Pending JP2017525755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014912P 2014-06-20 2014-06-20
US62/014,912 2014-06-20
US201462015661P 2014-06-23 2014-06-23
US62/015,661 2014-06-23
PCT/US2015/036414 WO2015195904A1 (en) 2014-06-20 2015-06-18 Her2 antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2017525755A JP2017525755A (ja) 2017-09-07
JP2017525755A5 true JP2017525755A5 (https=) 2018-07-26

Family

ID=54936097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519448A Pending JP2017525755A (ja) 2014-06-20 2015-06-18 Her2抗体−薬物抱合体

Country Status (16)

Country Link
US (1) US20160051695A1 (https=)
EP (1) EP3157560A4 (https=)
JP (1) JP2017525755A (https=)
KR (1) KR20170063507A (https=)
CN (1) CN106659783A (https=)
AU (1) AU2015277100A1 (https=)
BR (1) BR112016029588A2 (https=)
CA (1) CA2952834A1 (https=)
IL (1) IL249626A0 (https=)
MX (1) MX2016017117A (https=)
PH (1) PH12016502509A1 (https=)
RU (1) RU2017101331A (https=)
SG (2) SG10201811124YA (https=)
TW (1) TW201625315A (https=)
WO (1) WO2015195904A1 (https=)
ZA (1) ZA201700306B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
SG11201610620UA (en) 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
EP3769787A1 (en) * 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11661438B2 (en) * 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
JP7337698B2 (ja) * 2017-02-28 2023-09-04 シージェン インコーポレイテッド コンジュゲート化のためのシステイン突然変異抗体
EP4011396A1 (en) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
JP7073487B2 (ja) * 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
TW202003044A (zh) * 2018-03-09 2020-01-16 瑞典商奎亞培格製藥公司 可釋放之抗體結合物
EP3833690B1 (en) 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting cd47 and her2
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
AU2019340472A1 (en) * 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
EP3941927A4 (en) * 2019-03-22 2023-07-19 The Regents of The University of California COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES
CA3169792A1 (en) * 2020-03-05 2021-09-10 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN112618726B (zh) * 2020-12-21 2022-11-11 江南大学 一种抗体缀合物、增强抗体分子免疫效应功能的方法
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AR132368A1 (es) 2023-04-18 2025-06-18 Astrazeneca Ab Conjugados que comprenden enlazadores escindibles
WO2025059190A2 (en) * 2023-09-11 2025-03-20 Catena Biosciences, Inc. Polypeptide conjugation compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498298B2 (en) * 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005101017A1 (en) * 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
WO2010111018A1 (en) * 2009-03-06 2010-09-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
DK2528625T3 (da) * 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
AU2011243294C1 (en) * 2010-04-21 2015-12-03 Syntarga B.V. Novel conjugates of CC-1065 analogs and bifunctional linkers
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
RU2015129800A (ru) * 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
CN105899236B (zh) * 2014-01-10 2019-07-26 斯索恩生物制药有限公司 表现出改进的体内抗肿瘤活性的倍癌霉素adc

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Similar Documents

Publication Publication Date Title
JP2017525755A5 (https=)
RU2017101331A (ru) Конъюгаты антитело к her2 - лекарственное средство
US12285491B2 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
AU2021266317B2 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
JP2016508136A5 (https=)
RU2017101662A (ru) Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR102655301B1 (ko) 비스-링키지를 사용한 세포독성 약물의 접합
RU2017101681A (ru) Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения
KR20240095316A (ko) Bcma 단일클론 항체 및 항체-약물 접합체
JP2017528418A5 (https=)
JP2023530128A (ja) 細胞結合分子とカンプトテシン類縁体との共役体
JP2024510435A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2012522513A5 (https=)
JP2012522512A5 (https=)
KR20210117302A (ko) 분지형 링커를 갖는 아마니타 독소의 접합체
WO2020065408A1 (en) Sulfomaleimide-based linkers and corresponding conjugates
CN117120098A (zh) 内化的生物活性化合物缀合物的选择性药物释放
CN117120097A (zh) 内化的生物活性化合物缀合物的选择性药物释放
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
JP7853711B2 (ja) チューブリシン類縁体と細胞結合分子との共役体の製剤
HK40107212A (zh) 内化的生物活性化合物缀合物的选择性药物释放
NZ744940B2 (en) Conjugation linkers, antibody-drug conjugates thereof, and methods of synthesis and use of such conjugates